The annual general meeting in the Company on
Options granted under the share option program will normally vest equally over a three-year period from the date of grant and each option, when exercised, will give the right to receive one share in the Company at a fixed strike price set at time of grant. Options granted under the share option program expire eight years after grant date.
A total of 1,315,000 share options were granted, equal to 3.3% of total issued shares in the Company and 3.1% on a fully dilutive basis including all outstanding options. The strike price for this grant is
Share options granted in 2023 or earlier have been adjusted because of the reverse share split approved by the Annual General Meeting
Following today's grant the total issued share options equals 6.3% of the total issued shares in the Company and 5.9% on a fully dilutive basis. Total options outstanding after this grant are 2,464,765. Of this, 21,672 share options are vested and 2,443,093 not vested.
Of the total grant the following were granted to primary insiders (total holdings of share options following this grant):
In total 680,000 share options were granted to primary insiders.
The board considers an option program as an important element in attracting and retaining employees to foster long-term success. The board considers the option program terms and allocation to be at the market for comparable peers.
-End-
Contacts
CEO,
ir@bergenbio.com
CFO,
rune.skeie@bergenbio.com
Investor Relations / Media Relations
jl@lillebyfrisch.no
About
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
https://news.cision.com/bergenbio-asa/r/bergenbio-asa--grant-of-share-options,c4007259
https://mb.cision.com/Public/15728/4007259/b632328ded7b95a3.pdf
(c) 2024 Cision. All rights reserved., source